Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Animal Biotech.

Hallerman et al. 22 — Eric M. Hallerman, Virginia Polytechnic Institute and State University; Justin P. Bredlau, U.S. Department of Agriculture; Luiz Sergio A. Camargo, Brazilian Agricultural Research Corporation; Maria Lucia Zaidan Dagli, School of Veterinary Medicine and Animal Science, University of Sao Paulo; Margaret Karembu International Service for the Acquisition of Agri-Biotech Applications AfriCenter; Godfrey Ngure, International Service for the Acquisition of Agri-Biotech Applications AfriCenter; Rhodora Romero-Aldemita, ISAAA SEAsia Center; Pedro Jesu´s Rocha-Salavarrieta, InterAmerican Institute for Cooperation On Agriculture; Mark Tizard, Commonwealth Scientific and Industrial Research Organisation; Mark Walton; Diane Wray-Cahen, U.S. Department of Agriculture, 2022 (“Towards progressive regulatory approaches for agricultural

applications of animal biotechnology,” Transgenic Res, January, Available Online at https://link.springer.com/article/10.1007/s11248-021-00294-3, Accessed 07-13-2022)

Regulatory approval is a long and uncertain process in many countries, and regulatory uncertainty is a significant concern to both developers and academic

researchers. The experience of AquaBounty, with a 20-year regulatory and public acceptance pathway, has led to hesitancy among companies to invest heavily in animal biotechnology. Animal agricultural companies are awaiting examples of successful applications to pave the way for public acceptance. The regulatory landscape for animal biotechnology is continuing to evolve globally, with growing distinction between classical genetic modification using rDNA and more recent GnEd approaches used to generate changes that could occur through mutagenesis or conventional breeding. Unnecessary costs associated with non-risk-based regulatory frameworks may limit developments. Regulatory frameworks in some countries are costly and difficult to navigate, and can prove prohibitive to innovation, especially for academics and small companies developing technology. Public policies directly affect the choice of research topics. For example, basepair and gene deletions are easier to gain approval for through regulatory pathways than insertions, and thus research focuses on developing new traits through deletions. In Canada, proponents must put an economic value on a trait, which means that only highvalue traits are targeted. In several countries, there are two or more agencies involved in the approval of a

product. For example, in Australia food safety approval (conducted by FSANZ) is distinct from approval of the animal for commercial release (conducted by the Office of the Gene Technology Regulator). In Canada, it was recommended that a food safety evaluation be done for a GnEd animal although not required, as the trait was not novel, to ‘‘make the public more comfortable.’’ Of great concern to developers, breeders, and scientists are the lost opportunity costs—every year that existing technology is not used means avoidable costs in terms of disease prevention, animal welfare, and global food security (Van Eenennaam et al. 2021). Public trust in regulatory approaches and decisions is critical. Regulations may enable public trust by reassuring the public that products are safe, but also may generate safety concerns unsubstantiated by science (i.e., ‘‘if this is safe, then why is it so strictly regulated?’’). Likewise, how the product is regulated—e.g., as an animal drug or as a food animal — may alter consumer perception of safety in different

ways. This may be particularly confusing in the United States because a single nucleotide deletion in plants is exempt from biotechnology regulation, yet the same type of edit in an animal is regulated as a drug. Further, perception of agricultural biotechnology is also closely tied to negative perceptions of large corporations. Ironically, as seen most clearly with the plant biotechnology sector,1 the costly regulatory process allows mainly large corporations to gain approval of their products and limits commercialization of products developed by the academic or public sectors and small businesses, as well as limiting the type of traits developed (Whelan et al. 2020). This situation likely compounds public mistrust of such corporations and increases mistrust of the products at issue. Developers

suggested that regulations should be streamlined so that small firms and academic institutions also can afford the approval process and thereby shift GM and GnEd products from the association with large corporations. Overall, science-based regulatory development and modernization was recognized as a critical issue for moving animal biotechnology forward. Marketing and trade As countries continue to develop regulations, sharing guidelines and experience is key to encouraging harmonization to enable international trade. Currently, variation among regulatory systems and regulatory uncertainty have limited international trade of animal biotechnology products in several regions. Moreover, differences in definitions make tracing products of biotechnology, when required, challenging and expensive. New products will likely have to be accepted on a market-by-market basis as regulatory approaches and frameworks develop. The challenge of regulatory approval has caused companies to avoid pursuing marketing in some regions, while at the same time still engaging with regions that have a large influence on global developments (e.g., the European Union). Often developers will delay the commercialization of new products until export is possible into major markets, as demonstrated in the seed industry, where seeds for new approved crops are not released until approvals in key markets are obtained, delaying farmer access to new traits. Mutual recognition of regulatory decisions would facilitate trade and encourage innovation. There is some alignment of regulatory processes among South American countries. Labeling presents a particular challenge for trade of products from GnEd animals that do not have new DNA sequences or edits that distinguish them from conventionally-bred animals. The need for labels based on process when two products cannot be distinguished was questioned by researchers and developers. Already a lot of information that could be provided on labels is not (e.g., cattle breeds, antibiotic use), even when consumers may care about these characteristics. Part of the challenge is to avoid misleading consumers with labels when the meaning to the public is not clear. The objective of the label needs to be critically evaluated. In some cases, labeling products of GnEd could be beneficial if the product develops a reputation for sustainability or improved safety and may occur voluntarily, although this is far from certain. Marketing and trade require some degree of agreement or mutual understanding relative to regulatory processes among trading partners. With GM products developed with rDNA insertion, the regulatory processes and timelines are not harmonized globally, resulting in asynchronous approvals. There is only one GM animal developed for food use on the market; therefore, it is necessary to look to the plant biotechnology sector for examples and analysis of impacts of regulatory approaches. However, historically there has been general agreement among most countries regarding the definition of rDNA-derived plants and animals and what types of products are regulated. One major challenge with lack of harmonization of regulatory approaches for products of GnEd could be that different countries will make differing determinations as to the types of GnEd products that are regulated as conventional products versus those that will be regulated under their GMO regulations.

Sign in to recut, update, or save this card.